Reprieve Cardiovascular to Present at the 37th Annual Piper Sandler Healthcare Conference
Reprieve Cardiovascular, Inc., a clinical-stage company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), today announced that Mark Pacyna, Chief Executive Officer, will present at the 37th Annual Piper Sandler Healthcare Conference taking place December 2-4, 2025, in New York City.
Reprieve Cardiovascular Secures $61 Million Financing and Enrolls First Patient in Pivotal Study
Reprieve Cardiovascular, Inc., a clinical-stage company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), today announced the close of an oversubscribed $61 million Series B financing led by Deerfield Management and joined by Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, and Cadence Capital, as well as an undisclosed strategic investor. The financing combined equity investment with a debt facility to support the Company’s growth. Proceeds from the Series B financing will support the rapid execution of the global FASTR II pivotal clinical trial, which has now enrolled its first patient, as well as key commercial readiness activities.
Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial
Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results from its FASTR randomized pilot study, evaluating the Reprieve System for patients with ADHF compared to optimal diuretic therapy (ODT). The trial met both primary efficacy and safety endpoints. The results were presented by James Udelson, M.D., Principal Investigator of the FASTR trial and Chief of Cardiology and Interim Chief Physician Executive of the CardioVascular Center at Tufts Medical Center, during the Late-Breaking Clinical Science session at the Technology and Heart Failure Therapeutics (THT) Annual Meeting in Boston, Mass. The Company also announced they received Food and Drug Administration (FDA) approval to initiate an investigational device exemption (IDE) study, the FASTR II randomized pivotal trial, in the United States and Europe.
First-In-Human Study Demonstrates the Potential of the Reprieve System in Patients with Acute Decompensated Heart Failure
Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the first-in-human results of the Reprieve System at the CSI Focus D-HF (Device therapies in heart failure) conference in Frankfurt, Germany. Results of the study demonstrated the potential of the Reprieve System to safely accelerate and maximize decongestion while reducing the likelihood of kidney injury for patients with ADHF.
Reprieve Cardiovascular Completes Enrollment in Randomized Pilot Trial Evaluating First-of-its-Kind Personalized Fluid Management System for Acute Decompensated Heart Failure
Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced the completion of enrollment in the "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)" trial.
New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged
Reprieve Cardiovascular, Inc. (‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart Failure.
Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients
Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing. The total round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures. The funding will advance the Company’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
